Cipla: Sharp improvement in margins not likely to sustain
While the respiratory portfolio remains a significant part of the US portfolio, the peptides portfolio is a key watch in the near to medium term.
Latest News from Moneycontrol.com
Breaking News: Crown Equity Holdings, Inc. Appoints New Board Member

